Loading
HKSEHealthcareMedical - Pharmaceuticals
Latest quote
HK$5.25
−HK$0.23 · -4.20%
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Latest quote
HK$5.25
−HK$0.23 · -4.20%
Regular session · HKT · Market data may be delayed.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Day range
Current HK$5.25
52-week range
Current HK$5.25
Regular session · HKT · Market data may be delayed.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Day range
Current HK$5.25
52-week range
Current HK$5.25
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 31.83B CNY | 28.87B CNY | 26.2B CNY | 26.03B CNY | 26.86B CNY |
| Cost of goods sold | 5.71B CNY | 5.34B CNY | 4.99B CNY | 5.8B CNY | 5.33B CNY |
| Gross profit | 26.13B CNY | 23.53B CNY | 21.21B CNY | 21.54B CNY | 21.53B CNY |
| Research and development | 6.04B CNY | 5.23B CNY | 4.47B CNY | 4.33B CNY | 3.75B CNY |
| Selling, general, and administrative | 13.14B CNY | 12.16B CNY | 11.07B CNY | 12.56B CNY | 12.7B CNY |
| Operating expenses | 19.17B CNY | 17.39B CNY | 15.54B CNY | 15.95B CNY | 17.19B CNY |
| Interest income | 617.19M CNY | 499.56M CNY | 186.68M CNY | 195.91M CNY | 162.06M CNY |
| Interest expense | 271.11M CNY | 295.12M CNY | 495.24M CNY | 429.49M CNY | 308.62M CNY |
| Depreciation and amortization | 963.9M CNY | 939.85M CNY | 1.07B CNY | 1.05B CNY | 992.56M CNY |
| Operating income | 6.95B CNY | 6.14B CNY | 5.79B CNY | 5.59B CNY | 5.08B CNY |
| Net income | 2.34B CNY | 3.5B CNY | 2.33B CNY | 2.54B CNY | 14.61B CNY |
Company facts updated Sep 12, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS90.37M0.01%646.2B USD0.05%$87.14+1.00%
Vanguard FTSE Emerging Markets ETFVWO87.3M0.05%162.3B USD0.06%$60.35+0.69%
iShares Core MSCI Emerging Markets ETFIEMG80.76M0.05%162.15B USD0.09%$82.57+1.21%
iShares Core MSCI China ETF2801.HK33.81M0.28%12.21B HKD0.20%HK$24.20+1.51%
Avantis Emerging Markets Equity ETFAVEM25.22M0.09%28.6B USD0.33%$95.35+1.29%
Global X China Biotech ETF (HKD)2820.HK25.09M4.47%656.12M HKD0.68%HK$70.14-1.76%
iShares Core MSCI Asia ex Japan ETF3010.HK23.64M0.06%37.02B HKD0.28%HK$90.32-1.12%
iShares Core MSCI Asia ex Japan ETF83010.HK20.2M0.06%31.64B CNY0.28%CN¥77.04-1.76%Vanguard Total International Stock ETFVXUSVanguard FTSE Emerging Markets ETFVWOiShares Core MSCI Emerging Markets ETFIEMGiShares Core MSCI China ETF2801.HKAvantis Emerging Markets Equity ETFAVEMGlobal X China Biotech ETF (HKD)2820.HKiShares Core MSCI Asia ex Japan ETF3010.HKiShares Core MSCI Asia ex Japan ETF83010.HKAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
